+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years - 65Years
All Genders
Healthy Volunteers
ID07840612

Evaluating the Effects of Probenecid on Mirdametinib and Its Metabolites in Healthy Adults in an Open-Label Drug Interaction Study

Led by Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany · Updated on 2026-11-04

17

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are conducting a single-center, open-label study to assess how probenecid affects the pharmacokinetics of mirdametinib and its metabolites in healthy adult participants. The study aims to evaluate the changes in drug concentrations when both drugs are taken together, providing important information on drug interactions. The trial is sponsored by Merck Healthcare KGaA, Darmstadt, Germany, and includes healthy volunteers aged 18 to 65 years. Participants will receive oral mirdametinib capsules alone and in combination with oral probenecid tablets during two sequential periods within the study. The total study time for each participant is about 56 days, including a 28-day screening phase, a 19-day assessment phase covering both treatment periods, and a follow-up visit about 7 days after leaving the clinical research unit. The study is designed to observe how the presence of probenecid influences the levels of mirdametinib and its metabolites in the body. During the study, participants will undergo various medical evaluations including clinical chemistry, blood tests, urine tests, vital signs monitoring, ECGs, ophthalmic exams, and physical assessments. Blood samples will be collected to measure drug concentrations over the course of the treatment periods. Safety will be monitored by tracking adverse events and clinical laboratory findings. The entire participation duration is approximately 56 days, with close observation throughout the screening, treatment, and follow-up phases.

CONDITIONS

Brief Title

A Study to Assess the Effects of Probenecid on the Pharmacokinetics of Mirdametinib and Its Metabolites in Healthy Participants

Research Team

C

Communication Center

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here